Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 744

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 744
---
 and regulations promulgated thereunder.

Section 6. Termination . This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (a) such date and time as the Transaction Agreement is validly terminated in accordance with its terms without being consummated, (b) upon the mutual written agreement of all parties hereto to terminate this Subscription Agreement or (c) by written notice from Subscriber given any time on or after September 30, 2023, if the Closing has not occurred by such date and the terminating party’s breach was not the primary reason the Closing failed to occur by such date (the termination events described in clauses (a) — (c) above, collectively, the “ Termination Events ”); provided, that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination or common law intentional fraud in the making of any representation or warranty hereunder, and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from such breach or fraud. The Issuer shall notify Subscriber of the termination of the Transaction Agreement promptly after the termination thereof. Upon the occurrence of any Termination Event, except as set forth in the proviso to the first sentence of this Section 6 , this Subscription Agreement shall be void and of no further effect and any portion of the Purchase Price paid by Subscriber to the Issuer in connection herewith shall promptly (and in any event within one Business Day) following the Termination Event be returned to Subscriber.

Section 7. Trust Account Waiver . Reference is made to the final prospectus of IRIS dated as of March 4, 2021 and filed by IRIS with the SEC (File No. 333-252413) on March 8, 2021 (the “ Prospectus ”). Subscriber has reviewed the Prospectus and acknowledges that IRIS has established the trust account described in the Prospectus (the “ Trust Account ”) for the benefit of the public stockholders (the “ Public Stockholders ”) and the underwriters (“ Underwriters ”) of IRIS’s initial public offering (“ IPO ”) and that, except for certain exceptions described in the Prospectus, IRIS may disburse monies from the trust account only: (i) to the Public Stockholders in the event